Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10429387 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRPTPN1PTPN11 | |
| SCHEMBL21484050 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRPTPN1PTPN11 | |
| SCHEMBL10429374 | 0.98 | ALDH1A1 (0.36) | ALDH1A1TSHRPTPN1PTPN11 | |
| SCHEMBL987539 | 0.92 | TSHR (0.30) | ALDH1A1TSHR | |
| SCHEMBL16420274 | 0.87 | RAB9A (0.33) | — | |
| SCHEMBL31725737 | 0.84 | RAB9A (0.38) | — | |
| SCHEMBL9540191 | 0.81 | — | — | |
| SCHEMBL20639270 | 0.81 | — | — | |
| SCHEMBL2121918 | 0.77 | PTPN7 (0.40) | ALDH1A1TSHR | |
| SCHEMBL789558 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| EP-3981766-A1 | INDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2022-04-13 | — | — | EP | disclosed |
| CN-113024466-A | Tetra-substituted olefin compound and use thereof | 卫材 R&D 管理有限公司 | 2021-06-25 | — | — | CN | disclosed |
| CN-107847498-B | Tetra-substituted olefin compound and use thereof | 卫材R&D管理有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-12-01 | — | — | US | disclosed |
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110059982-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110020837-A1 | Method for isolating or identifying a target protein interacting with a lipid in a cell | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| EP-2250170-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Merck Patent GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009112139-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | MERCK PATENT GMBH, (DE) | 2009-09-17 | — | — | WO | disclosed |
| US-5026874-A | Agricultural insecticides | WELLCOME FOUNDATION LIMITED (GB) | 1991-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851065-B2 | Tetrasubstituted alkene compounds and their use | BRCA1, ESR2, ESR1 | ALDH1A1 1046/4885TSHR 1390/4885PTPN1 2477/4885 |
| US-20110020837-A1 | Method for isolating or identifying a target protein interacting with a lipid in a cell | PLIN5, PLIN1, PLIN3 | ALDH1A1 3031/4885TSHR 1564/4885PTPN1 4237/4885 |
| US-20120071535-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ALDH1A1 1178/4885TSHR 180/4885PTPN1 824/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | ALDH1A1 3665/4885TSHR 1312/4885PTPN1 648/4885 |
| US-20110059982-A1 | AZAINDOLE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | PMP22, PNMT, GRIN2C | ALDH1A1 1711/4885TSHR 711/4885PTPN1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.